This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giusti, R. M. Articles by Pazdur, R. Search for Related Content PubMed PubMed Citation Articles by Giusti, R. M. Articles by Pazdur, R.

Regulatory Issues: FDA

FDA Drug Approval Summary: Panitumumab (Vectibix^TM)

Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

Key Words. Panitumumab • Colorectal cancer • Advanced resistant/refractory disease • Drug approval

Correspondence: Ruthann M. Giusti, M.D., Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993, USA. Telephone: 301-796-2320; Fax: 301-796-9849; e-mail: ruthann.giusti{at}fda.hhs.gov

On September 27, 2006, the U.S. Food and Drug Administration granted approval to panitumumab (Vectibix^TM, Amgen, Inc., Thousand Oaks, CA) for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab approval is based on the results of a single, open-label, randomized, multinational study that enrolled 463 patients with EGFR-expressing (at least 1+ membrane staining in 1% of tumor cells) metastatic colorectal cancer. Patients were randomized to either best supportive care (BSC) alone or BSC plus panitumumab, 6 mg/kg i.v., every other week. The primary study endpoint was progression-free survival (PFS), determined by an independent review committee that was blinded as to treatment assignment. BSC patients who progressed were eligible to receive panitumumab.

The study patients' median age was 62 years, with 40% aged 65; 63% were male, 99% were white, 86% had a baseline Eastern Cooperative Oncology Group performance status score of 0 or 1, and 67% had colon cancer. The median time from diagnosis of metastases was approximately 19 months and the median number of prior therapies was 2.4. The PFS duration was significantly longer among patients randomized to receive panitumumab in addition to BSC (n = 231) compared with BSC alone (n = 232). The median and mean PFS times were 56 and 96.4 days, respectively, for patients receiving panitumumab and 51 and 59.7 days, respectively, for patients receiving BSC alone. Nineteen partial responses (8%, 95% confidence interval [CI], 5.3%–12.5%) were observed in panitumumab treated patients. The median duration of response was 17 weeks (95% CI, 16–25 weeks). Approximately 75% of patients in the BSC alone arm crossed over to receive panitumumab after disease progression. There was no difference in overall survival between the two study arms. The most common adverse events were skin rash, hypomagnesemia, paronychia, fatigue, abdominal pain, nausea, and diarrhea. The most serious adverse events were pulmonary fibrosis, severe dermatologic toxicity complicated by infectious sequelae and septic death, infusion reactions, abdominal pain, hypomagnesemia, nausea, vomiting, diarrhea, and constipation.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				R. Sridhara, J. R. Johnson, R. Justice, P. Keegan, A. Chakravarty, and R. Pazdur Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007 J Natl Cancer Inst, February 24, 2010; 102(4): 230 - 243. [Abstract] [Full Text] [PDF]

				I. J. Dahabreh, H. Linardou, F. Siannis, P. Kosmidis, D. Bafaloukos, and S. Murray Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Clin. Cancer Res., January 1, 2010; 16(1): 291 - 303. [Abstract] [Full Text] [PDF]

				E. GIANNOPOULOU, A. ANTONACOPOULOU, P. MATSOUKA, and H. P. KALOFONOS Autophagy: Novel Action of Panitumumab in Colon Cancer Anticancer Res, December 1, 2009; 29(12): 5077 - 5082. [Abstract] [Full Text] [PDF]

				C. Gridelli, P. Maione, M. L. Ferrara, and A. Rossi Cetuximab and Other Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Non-Small Cell Lung Cancer Oncologist, June 1, 2009; 14(6): 601 - 611. [Abstract] [Full Text] [PDF]

				R. M. Giusti, M. H. Cohen, P. Keegan, and R. Pazdur FDA Review of a Panitumumab (VectibixTM) Clinical Trial for First-Line Treatment of Metastatic Colorectal Cancer Oncologist, March 1, 2009; 14(3): 284 - 290. [Abstract] [Full Text] [PDF]

				I Zlobec and A Lugli Prognostic and predictive factors in colorectal cancer Postgrad. Med. J., August 1, 2008; 84(994): 403 - 411. [Abstract] [Full Text] [PDF]

				I Zlobec and A Lugli Prognostic and predictive factors in colorectal cancer J. Clin. Pathol., May 1, 2008; 61(5): 561 - 569. [Abstract] [Full Text] [PDF]

				E. L. Kwak, J. W. Clark, and B. Chabner Targeted Agents: The Rules of Combination Clin. Cancer Res., September 15, 2007; 13(18): 5232 - 5237. [Abstract] [Full Text] [PDF]